- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/755 - Facteurs VIII
Détention brevets de la classe C07K 14/755
Brevets de cette classe: 835
Historique des publications depuis 10 ans
|
72
|
57
|
74
|
56
|
50
|
50
|
45
|
39
|
41
|
13
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Bioverativ Therapeutics Inc. | 214 |
89 |
| Takeda Pharmaceutical Company Limited | 2719 |
57 |
| Octapharma AG | 203 |
27 |
| The Children's Hospital of Philadelphia | 838 |
21 |
| Novo Nordisk A/S | 2301 |
21 |
| CSL Limited | 249 |
15 |
| St. Jude Children's Research Hospital | 239 |
15 |
| CSL Behring Lengnau AG | 125 |
15 |
| The Trustees of the University of Pennsylvania | 4398 |
14 |
| CSL Behring GmbH | 350 |
14 |
| Baxalta Incorporated | 300 |
13 |
| Bayer HealthCare LLC | 1305 |
12 |
| Baxalta GmbH | 103 |
12 |
| Emory University | 1694 |
12 |
| UCL Business Ltd | 650 |
11 |
| Baxter International Inc. | 1891 |
10 |
| Baxter Healthcare S.A. | 1387 |
10 |
| Georgia Tech Research Corporation | 2897 |
10 |
| BioMarin Pharmaceutical Inc. | 383 |
10 |
| Spark Therapeutics, Inc. | 176 |
9 |
| Autres propriétaires | 438 |